Morgan Stanley
ALZN icon

Morgan Stanley’s Alzamend Neuro ALZN Stock Holding History

Morgan Stanley’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.1K Hold
18,000
– – ﹤0.01% 6748
2025
Q4 		$32.8K Buy
+18,000
New +$40.8K ﹤0.01% 6555
2025
Q2 		– Hold
0
– -$3 – 8098
2025
Q1 		– Hold
0
– – – 8050
2024
Q4 		– Hold
0
– – – 7940
2024
Q3 		– Hold
0
– – – 7886
2024
Q2 		– Hold
0
– – – 7770
2024
Q1 		– Sell
-1
Closed -$86 – 7603
2023
Q4 		$58 Buy
+1
New +$164 ﹤0.01% 7623
2023
Q3 		– Hold
0
– – – 7432
2023
Q2 		– Sell
-2
Closed -$1.57K – 7434
2023
Q1 		$1.26K Sell
2
-3
-60% -$2.26K ﹤0.01% 7320
2022
Q4 		$3.77K Buy
5
+2
+67% +$2.9K ﹤0.01% 7224
2022
Q3 		$4K Hold
3
– – ﹤0.01% 7286
2022
Q2 		$3K Hold
3
– – ﹤0.01% 7496
2022
Q1 		$5K Buy
+3
New +$5.63K ﹤0.01% 7570
2021
Q4 		– Hold
0
– -$1K – 7964
2021
Q3 		– Hold
0
– – – 7749
2021
Q2 		– Hold
0
– – – 7515

Other funds holding ALZN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Morgan Stanley's ALZN Position: Q1 2026 in Review

Morgan Stanley held its Alzamend Neuro (ALZN) position steady in Q1 2026 at 18,000 shares worth $19.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6748.

Morgan Stanley first reported a position in ALZN in Q1 2022 and has held it in 8 quarters since. The position peaked at $32.8K in Q4 2025. 12 funds tracked by Wall St. Rank hold ALZN as of Q1 2026.

  • Morgan Stanley held 18,000 shares of Alzamend Neuro worth $19.1K as of Q1 2026.
  • Morgan Stanley left its Alzamend Neuro share count unchanged in Q1 2026.
  • Alzamend Neuro made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6748 holding.
  • Morgan Stanley first reported a position in Alzamend Neuro in Q1 2022 and has held it in 8 quarters since.
  • Morgan Stanley's Alzamend Neuro position peaked at $32.8K in Q4 2025.
  • 12 funds tracked by Wall St. Rank held Alzamend Neuro as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.